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1.

Introduction
Prostate cancer (PCa) is one of the most commonly diagnosed cancers in men [1] . Incidence in recent years has been increasing worldwide and is expected to continue with the current ageing population; this increase poses a global major health and economic burden on society. Intermittent hormonal therapy (IHT) with antiandrogens is used increasingly to improve the quality of life (QoL) of PCa patients without diminishing the efficacy of chronic androgen-deprivation therapy (ADT). ADT is the current standard therapy for advanced PCa or cancer that has metastasised beyond the prostate. To maximise the efficacy and tolerability of ADT while reducing adverse events, it is possible for some patients to alternate treatment and offtreatment periods.
Few randomised studies have compared the efficacy of IHT with continuous therapy; however, available data suggest that IHT is at least as effective as continuous treatment in the management of advanced PCa with regard to both disease progression and overall survival (OS) [2] [3] [4] [5] . Further potential benefits of IHT include reduced sideeffects compared with continuous therapy, improved QoL (especially recovery of sexual potency), health care cost savings, and delayed emergence of hormonal refractoriness [6] [7] [8] . However, no randomised studies to date have assessed IHT delivered as monotherapy with antiandrogens (cyproterone acetate; CPA).
This study aimed to demonstrate the noninferiority of antiandrogen monotherapy with CPA IHT compared with continuous maximal androgen blockade (MAB) therapy.
The European Association of Urology recently acknowledged that intermittent ADT (IADT) is already offered to patients with advanced PCa and stated in its guidelines that IADT should no longer be considered experimental [1] .
2.
Patients and methods 
Patients
Inclusion criteria were histologically confirmed prostate adenocarcinoma, cT3-cT4 M0 and M1, serum prostate-specific antigen (PSA) 4 ng/ml and 100 ng/ml, age 80 yr, World Health Organisation performance status 0-2, and normal liver function not suitable for definitive treatment. Exclusion criteria were previous hormonal therapy or chemotherapy, presence of another neoplasm (except skin, excluding melanoma), severe concomitant chronic disease, or expected follow-up difficulties. Prior surgery and radiotherapy were reasons for exclusion.
Clinical stage was assessed by the investigator in each centre, and there was no central pathology review.
Intervention
All specifying noninferiority) versus the alternative (HR: 1) was used for the main outcome of OS and a one-sided test. Cox regression models were used to account for the effect of prognostic factors. Cause-specific deaths were analysed by assessing competing risks [9, 10] using the cmprsk library in R v.2.2-2 (R Foundation, Vienna, Austria). Mixed-effect regression models were used to investigate the trends in PSA and QoL scores during the course of the study. Results are reported at the 5% significance level, and 95% CIs are used for all estimated effects.
The Benjamini and Hochberg procedure [16] was used to adjust for multiple testing of the subscores in the QoL analysis.
Results
In total, 1045 patients were recruited and 918 patients were randomised, 462 to IHT and 456 to continuous treatment. Patient and disease characteristics at randomisation are shown in Table 1 . The patient distribution was similar in the two treatment groups ( Table 1) . The median PSA level at recruitment (before induction therapy) of patients that were subsequently randomised was 15 ng/ml and then 1.4 ng/ml after the induction period, with 31% having PSA 0.5 ng/ml. PSA level, Gleason score, and metastatic status at baseline were the only independent predictors of PSA level at randomisation; T stage, tumour grade, and age had no effect. PSA level at randomisation increased with higher baseline Gleason scores: Gleason score 2-4, median PSA level 0.6 ng/ml; Gleason score 5-6, median PSA level 0.7 ng/ml; Gleason score 7-8, median PSA level 1.2 ng/ml; Gleason score 9-10, median PSA level 1.6 ng/ml ( p < 0.001).
The median follow-up time from randomisation was 66 mo (maximum: 12 yr), and 56% of patients were observed for >5 yr; 393 patients were alive at the last follow-up. Progression was reported in 299 patients, 168 in the IHT arm and 131 in the continuous arm ( Table 2) . 
Among patients with complete information on progression, there were slightly more progressions among those on IHT Fig. 1 ). The upper 95% confidence limit is less than the 1.21 limit specified in the design demonstrating noninferiority of IHT relative to continuous treatment. Both PSA and metastatic status at randomisation were independently associated with survival ( Fig. 1) , and there was evidence of a trend for an interaction of PSA with treatment ( p = 0.05); intermittent therapy was more effective than continuous therapy among patients with PSA 1 ng/ml (HR: 0.79; 95% CI, 0.61-1.02, p = 0.07). Another 69 patients, 25 on continuous therapy and 44 on IHT, progressed but were still alive at the time the analysis took place. There was no evidence of any difference between continuous therapy and IHT in terms of PFS (HR: 1.01; 95% CI, 0.86-1.19; p = 0.89). Metastatic status, age, PSA, and Gleason score were all independently associated with PFS (Table 3a) .
The number of deaths due to any cancer, PCa, second primary cancer/other malignant disease (OMD), cardiovascular death (CVD), and other/unknown causes were similar between treatment arms ( Table 2) . The competing risks analysis showed that the slightly reduced hazard of dying in the group on IHT resulted primarily from fewer deaths from CVD balanced by an increased risk of death from a second primary cancer (Table 3b) . None of these differences in HR was statistically significant (Table 3b) . Both metastatic status and PSA level at randomisation were associated with death from PCa but not with OMD or other causes of death (Table 3b ). Adjusting for metastatic status and PSA at randomisation, the HR of dying from one of the four causes was similar to the unadjusted values.
Safety and quality of life
Side effects were generally reported more frequently among patients on continuous therapy (Table 4 ). Summary QLQ-C30 totals were similar between study arms (2.1 points lower [worse QoL; standard error (SE): 1.27] in the continuous arm compared with the intermittent arm; p = 0.11) during 60 mo of follow-up. QLQ-C30 scores decreased in both arms, from 83.4 (SE: 1.96) at baseline to 70.5 (SE: 0.96) after 60 mo, and the gradient of the decline was similar in the two arms ( p = 0.94). During follow-up, the only differences between the two groups of patients were in relation to the symptoms and sexual activity questions in the EORTC Prostate Cancer Module, with a significantly higher proportion of patients in the continuous arm reporting symptoms of hot flushes, gynaecomastia and swelling of the legs ( p = 0.0001), and sexual problems ( p = 0.003). Reported sexual activity decreased in both arms during the study, although sexual activity was significantly greater ( p < 0.0001) in the IHT arm. Shortly after randomisation, with the majority of patients in the IHT arm off therapy, the level of sexual activity after 6 mo in this group was similar to pretreatment levels (31.3% and 32.7%, respectively); sexual activity then decreased as progressively more patients in the IHT arm received CPA therapy. However, at 30 mo after randomisation, the proportion of patients reporting sexual activity was significantly greater in the IHT arm than in the continuous arm (24.9% of 226 patients vs 6.4% of 145 patients, respectively; p < 0.0001).
Among the 462 patients randomised to IHT, 50% were off therapy for at least 2.5 yr following randomisation (Table 5) and 28% were off-therapy for >5 yr. The median time off therapy for patients whose PSA levels were 1 ng/ml and 1-4 ng/ml was 3.1 yr and 2.1 yr, respectively (Table 5) . Patients returning to therapy had a median of 20 wk of treatment (16.7 wk and 26 wk for those with PSA levels <1 ng/ml and 1-4 ng/ml, respectively), which was followed by a second period off therapy (Table 5) . Only 121 of patients on IHT had two returns to therapy postrandomisation, and this was for a median of 19.6 wk (Table 5 ).
Discussion
Two observations have considerable clinical importance:
(1) a 3-mo period of induction therapy was used in this study, as in SEUG 9401 [2] , and (2) patients in the intermittent arm who were on therapy received CPA 300 mg/d as monotherapy. This intermittent protocol is the first using antiandrogen monotherapy, and the study demonstrated that intermittent monotherapy with CPA 300 mg/d was noninferior to continuous therapy in terms of OS. Indeed, the hazard of dying on intermittent therapy was 20% lower than on continuous therapy in patients with a PSA level 1 ng/ml after induction therapy. The study is reporting early in terms of numbers of deaths, as all randomised patients had been followed for at least 5 yr. The death rate was lower than anticipated, and the estimated proportion of patients surviving at 5 yr was 61%, with a median survival time of 6.6 yr compared with the anticipated 4.5 yr. By October 2012, there were 525 deaths and 106 deaths were accumulated over the last 2 yr follow-up. Thus a further 2 yr follow-up, at least, would be needed to accrue the additional 133 deaths required to reach the 658 deaths specified in the protocol. In addition, noninferiority of intermittent therapy compared with continuous therapy was demonstrated in terms of OS. There was also no evidence of any difference in terms of PFS, and with an HR of 1.01 (95% CI, 0.86-1.19), it is clear that noninferiority of IHT compared with continuous therapy can also be demonstrated for PFS. Metastatic status, PSA level at randomisation, Gleason score, and age were independent predictors of PFS, with age 60-74 yr, M0, low Gleason score, and low PSA associated with longer duration of PFS.
In this study, 50% of patients receiving IHT were off therapy for at least 2.5 yr following initial LHRH therapy, and 28% were off therapy for >5 yr. These findings support the work of Seruga and Tannock, with data collected from >1000 randomised patients indicating that IADT should be regarded as standard therapy [11] for specific patient groups. In 2007, Shaw et al. performed a meta-analysis of 1446 patients from international phase 2 studies and concluded that the duration of biochemical remission after a period of hormone therapy was a durable early indicator of how rapidly androgen-independent PCa and death would occur [12] .
In our study, although not significant, more deaths from any cancer occurred in the IHT arm, but more deaths from CVD occurred in the continuous treatment arm. In contrast, although there were no differences between study arms in the domains of the QLQ-C30, side effects were generally less commonly reported in the intermittent arm. Patients on intermittent therapy experienced fewer sexual problems and reported greater sexual activity than patients on continuous therapy. During follow-up, although progressively more patients in the intermittent arm were on therapy and sexual activity decreased, sexual activity was still significantly higher than among patients on continuous therapy. Similar results have been reported in SEUG 9401 [2] and in other studies [6, [13] [14] [15] . In protocol S9346 from Hussein et al. [3] , IADT was proven to be noninferior to continuous deprivation in patients with extensive disease; however, intermittent therapy was statistically inferior in patients with minimal disease, suggesting that continuous therapy would be the preferred treatment in this group. In contrast, there was no difference between minimal disease and extended disease in our trial.
Conclusions
From this study we can conclude that IHT should be considered as the standard therapy for patients who are not suitable for definitive therapy with advanced PCa because IHT is noninferior to continuous therapy with regard to OS. In addition, IHT is associated with better QoL (ie, sexual life) and lower costs for communities than continuous therapy. This study also showed that an induction period of 3 mo is adequate to sufficiently reduce PSA levels. Based on results from SEUG 9401 [2] and 9901, we can define an optimal candidate for intermittent therapy as a patient with (1) M0, (2) T3, and (3) PSA levels prior to induction therapy <100 ng/ml whose PSA decreases to <4 ng/ml (preferably <1 ng/ml) after 3 mo of induction therapy. Intermittent therapy is less likely to be beneficial for patients with metastasis and bone hot spots, with high initial PSA levels (>100 ng/ml), or with severe pain or extensive disease.
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